[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365127-105":59,"doc-detail-365127-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-bioinformatics-and-immunohistochemical-analyses-identify-phosphoinositide-metabolism-and-pnpla7-as-potential-biomarkers-in-urological-cancers","Comprehensive bioinformatics and immunohistochemical analyses identify phosphoinositide metabolism and PNPLA7 as potential biomarkers in urological cancers","","Phosphoinositides (PI) and metabolic enzymes regulate processes linked to cancer hallmarks, yet their roles in urinary tract (urological) cancers remain insufficiently defined. This work performs large-scale bioinformatic analysis across clear cell renal carcinoma, bladder cancer, and prostate adenocarcinoma using public databases to compute PI metabolism scores, predict drug sensitivity and immune profiles, and conduct risk stratification. Single-cell RNA sequencing is used to map PI metabolism-associated intercellular communication networks. The study highlights PNPLA7 as a potential biomarker, validated by immunohistochemistry on clinical samples, and supports PI metabolism as a prognostic biomarker that may inform targeted therapies and immunosuppressive approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-bioinformatics-and-immunohistochemical-analyses-identify-phosphoinositide-metabolism-and-pnpla7-as-potential-biomarkers-in-urological-cancers/365127/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-bioinformatics-and-immunohistochemical-analyses-identify-phosphoinositide-metabolism-and-pnpla7-as-potential-biomarkers-in-urological-cancers/365127.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the study on PI metabolism in urological cancers?","Question",{"text":112,"@type":113},"To characterize PI metabolism across kidney clear cell renal carcinoma, bladder cancer, and prostate adenocarcinoma, and to assess its contribution to clinical phenotypes using computational analyses and additional single-cell insights.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were PI metabolism scores and related analyses performed?",{"text":117,"@type":113},"PI metabolism activity was quantified computationally, followed by multi-dimensional exploration of associated processes, key genes, patient prognosis, tumor microenvironment, molecular subtypes, and drug sensitivity.",{"name":119,"@type":110,"acceptedAnswer":120},"How was PNPLA7 identified and validated?",{"text":121,"@type":113},"The analyses identified PNPLA7 as a potential biomarker in urological cancers, and the finding was validated using immunohistochemical evaluation of clinical samples.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365127,1791196173,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nComprehensive bioinformatics and immunohistochemical analyses identify phosphoinositide metabolism and PNPLA7 as potential biomarkers in urological cancers  \nYinhao Chen1,4, Mingde Gao2,4, Peng Chen1,4, Amit Sharma1, Maria Fitria Setiawan1, Maria A. Gonzalez-Carmona3, Xiaolin Wang2􀀍 & Ingo G. H. Schmidt-Wolf1􀀍  \nPhosphoinositides (PI) and their metabolic enzymes are known to be involved in cellular processes associated with the hallmarks of cancer. The impact of PI metabolism-related components on urinary tract (or urological) cancers, however, remains unexplored. Considering this, herein, we performed a comprehensive bioinformatic analysis on clear cell renal carcinoma, bladder cancer, andadenocarcinoma of the prostate using public databases to investigate the relative contribution of PI metabolism in these clinical phenotypes. Primarily, we computed phosphoinositide metabolism scores to assess the associated biological processes and further enriched the analysis by predicting drug sensitivity, immune profiling, and risk stratification. Besides, we utilized single-cell RNA sequencing datasets to identify intercellular communication networks associated with PI metabolism in these cancer subtypes. Of interest, our analysis identified the PNPLA7 gene as a potential biomarker inurological cancers, which we validated using immunohistochemical evaluation of clinical samples. In conclusion, our study reveals that PI metabolism is a critical prognostic biomarker for urological cancers and may guide drug therapies, including immunosuppressants. Therefore, PNPLA7 could serve as a potential target and requires further attention.  \nKeywords Urological cancers, Phosphoinositide metabolism, Machine learning, Bioinformatics, Risk stratification  \nUrological cancers, including kidney, bladder, and prostate cancer, impose a substantial burden on global health1–3. Treatment modalities for these malignancies are diverse, ranging from surgical interventions, such as radical prostatectomy for urological cancers, to advanced therapeutic strategies4–6. Immunotherapy, particularly immune checkpoint inhibitors, has shown great promise in urological cancers, with PD-L1 expression serving asa valuable predictive biomarker7. In addition, targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, play a crucial role in managing these neoplasms8. Despite these therapeutic advancements, significant challenges remain, particularly in bladder cancer, where high recurrence rates and progression to invasive disease are prevalent9. These issues underscore the need for continued research into novel therapeutic strategies and the identification of new biomarkers.  \nPhosphoinositides (PI) metabolism plays a critical role in numerous cellular functions, including lipid metabolism and signal transduction pathways10. Research has demonstrated that phosphoinositide 3-kinase (PI3K) inhibitors can modulate immune responses and induce metabolic alterations, underscoring the complex  \n1Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital of Bonn, Venusberg Campus 1, 53127 Bonn, Germany. 2Department of Urology, Affiliated Tumor Hospital of Nantong University and Nantong Tumor Hospital, No. 30, Tongyang North Road, Tongzhou District, Nantong 226361, Jiangsu, People’s Republic of China. 3Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.  \n4Yinhao Chen, Mingde Gao, and Peng Chen contributed equally to this work. 􀀍 email: [cxhwyc2010@163.com](cxhwyc2010@163.com); [ingo.schmidt-wolf@ukbonn.de](ingo.schmidt-wolf@ukbonn.de)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nrelationship between PI metabolism and immune regulation11. In cancer, dysregulation of phosphatidylinositol signaling pathways has been implicated in tumorigenesis and cancer progression12. The PI3K pathway, frequen","cbCaigvSR8QUkeAf","https://ap.wps.com/l/cbCaigvSR8QUkeAf","pdf",8836571,14,"English","# Methods\n## Data acquisition","[{\"question\":\"What is the main objective of the study on PI metabolism in urological cancers?\",\"answer\":\"To characterize PI metabolism across kidney clear cell renal carcinoma, bladder cancer, and prostate adenocarcinoma, and to assess its contribution to clinical phenotypes using computational analyses and additional single-cell insights.\"},{\"question\":\"How were PI metabolism scores and related analyses performed?\",\"answer\":\"PI metabolism activity was quantified computationally, followed by multi-dimensional exploration of associated processes, key genes, patient prognosis, tumor microenvironment, molecular subtypes, and drug sensitivity.\"},{\"question\":\"How was PNPLA7 identified and validated?\",\"answer\":\"The analyses identified PNPLA7 as a potential biomarker in urological cancers, and the finding was validated using immunohistochemical evaluation of clinical samples.\"}]","Comprehensive bioinformatics and immunohistochemical analyses identify phosphoinositide metabolism and PNPLA7 as potential biomarkers in urological cancers | PDF",1790160119,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5d7cb5fae27e0e08be604e9cef119c7.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a52c8ee1d8362373bb74e8389b4a303.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/618140eee56ba4cc7f46f77029f18785.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54ee05a55ed92f8a2edf6c6a351710ff.webp",980,1287]